Related Experiment Video
Updated: Mar 15, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Resected small cell lung cancer-time for more?
Alissa S Marr1, Chi Zhang2, Apar Kishor Ganti3
1Division of Oncology-Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA ;
Abstract:
Small cell lung cancer (SCLC) often presents with either regional or systemic metastases, but approximately 4% of patients present with a solitary pulmonary nodule. Surgical resection can be an option for these patients and is endorsed by the National Comprehensive Cancer Network (NCCN) guidelines. There are no prospective randomized clinical trials evaluating the role of adjuvant systemic therapy in these resected SCLC patients. A recent National Cancer Database analysis found that the receipt of adjuvant chemotherapy alone [hazard ratio (HR), 0.78; 95% CI, 0.63-0.95] or with brain radiation (HR, 0.52; 95% CI, 0.36-0.75) was associated with significantly improved survival as compared to surgery alone. As it is unlikely that a randomized prospective clinical trial addressing this question will be completed, these data should assist with decision making in these patients.
Insights
For small cell lung cancer (SCLC) presenting as a solitary pulmonary nodule, adjuvant chemotherapy or chemotherapy with brain radiation after surgery significantly improves survival. These findings aid treatment decisions for resected SCLC patients.
Area of Science:
- Oncology
- Thoracic Surgery
- Medical Oncology
Background:
- Small cell lung cancer (SCLC) typically presents with metastatic disease.
- A small subset of SCLC patients (approx. 4%) may present with a solitary pulmonary nodule, amenable to surgical resection per NCCN guidelines.
- The role of adjuvant systemic therapy following surgical resection for these early-stage SCLC patients remains underexplored due to a lack of prospective trials.
Discussion:
- A National Cancer Database analysis suggests adjuvant chemotherapy alone or combined with brain radiation improves survival in resected SCLC.
- The hazard ratios indicate a significant survival benefit for both adjuvant chemotherapy regimens compared to surgery alone.
- Given the unlikelihood of future randomized trials, these retrospective data are crucial for clinical decision-making.
Key Insights:
- Adjuvant chemotherapy following surgical resection is associated with improved survival in select small cell lung cancer patients.
- The addition of brain radiation to adjuvant chemotherapy further enhances survival benefits.
- Retrospective data analysis provides valuable evidence for treatment strategies in early-stage SCLC.
Outlook:
- Further research into optimal adjuvant systemic therapy for resected SCLC is warranted.
- These findings may influence current treatment guidelines for early-stage SCLC.
- The study highlights the importance of retrospective data analysis in the absence of prospective trials.
More Related Videos
11:17Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer
Published on: February 27, 2026
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019